If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
169
results.
Updated on
14/09/2026 [06:47:00]
Results 150 to 169 of 169
Absstract of: US20260265829A1
Provided herein are lncRNAs and methods for diagnosing cardiac pathologies in a subject. Also provided are methods for treating a cardiac pathology in a subject comprising administering to said subject an effective amount of a modulator of one or more lncRNAs.
Absstract of: WO2025093713A1
The present invention relates to a method for identifying a compound that increases the expression, amount and/or biological activity of the gene ZBTB16 in a cell of a subject, in particular a cardiac cell. Further provided are pharmaceutical compositions comprising compounds that increase the expression, amount and/or biological activity of the gene ZBTB 16 in a cell of a subject for use in medicine, in particular for use in the prevention or treatment of cardiovascular pathologies in a subject, in particular age-induced diastolic dysfunctions. Further provided are diagnostic methods, and kits.
Absstract of: WO2025085784A1
Disclosed herein are methods, compositions, and devices for use in diagnosis and treatment of disease, including cardiovascular disease, and such disease and dysfunction as related to cancer therapy administration. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more biomarkers that are indicative of a cardiovascular disease and dysfunction.
Absstract of: US20260242872A1
0000 The present invention relates to a long non-coding RNA as a therapeutic target in cardiac disorders.
Absstract of: WO2026167636A2
The present invention provides methods, systems, platforms, kits and computer- implemented processes for predicting, diagnosing, classifying, profiling diabetes, prediabetes (or intermediate hyperglycemia) and diabetes-related cardiometabolic disorders and complications in a subject, and for performing precision treatment selection and clinical decision-making. In some embodiments, the invention comprises individual modules, wherein each module generates outputs comprising one or more of disease risk stratification, subtype classification, complication risk prediction, pharmacogenomic predictions, and treatment recommendations. In certain embodiments, the invention further provides an integrated, multi-method, multi-functional system, platform, kit or computer-implemented method wherein two or more of the individual modules are integrated to generate individualized health data for personalized management, selection for participation in clinical trials and generation of real-world evidence to complement clinical trial evidence for evaluation of safety, tolerability, clinical effectiveness and cost-effectiveness of interventions. Other example embodiments are described herein.
Absstract of: US20260235604A1
The present invention relates to the Asparagine Synthetase (Asns) gene and the role it plays in cardiomyocyte dedifferentiation and cardiac regeneration. More particularly, the invention is directed to the detection of ASNS expression as a diagnostic marker for cardiomyocyte dedifferentiation and cardiac regeneration; therapeutic up- and downregulation of ASNS expression to augment dedifferentiation-regeneration or suppress dedifferentiation-regeneration; and methods of screening for ASNS inhibitors, activators and regulators of cardiomyocyte dedifferentiation activity. Also disclosed are vectors, probes, therapeutics and kits.
Absstract of: WO2026170058A1
Methods, kits, and computer-implemented systems are provided for diagnosing, predicting, or treating atherosclerosis or progression thereof in a subject.
Absstract of: US20260234726A1
This invention relates to a biomarker combination, diagnostic kits and methods for diagnosis of dilated cardiomyopathy, and use of the biomarker combination in preparation of the diagnostic kits for dilated cardiomyopathy. The biomarker combination comprises miR-126-5p and a tyrosine phosphorylation level of PECAM-1 proteins, wherein an expression level of miR-126-5p is upregulated in patients with dilated cardiomyopathy, and the tyrosine phosphorylation level of PECAM-1 protein is increased in the patients with the dilated cardiomyopathy.
Absstract of: KR20260122752A
본 발명은 요독성 심근병증 진단용 신규 바이오마커 및 이의 용도에 관한 것으로, 요독성 심근병증 진단용 신규 바이오마커를 발굴함으로써 요독성 심근병증을 조기에 진단하고 적합한 치료법을 제공하여 환자의 예후 개선, 의료비 절감 등에 기여할 수 있다.
Absstract of: WO2026164500A1
The present invention relates to a novel biomarker for the diagnosis of uremic cardiomyopathy and use thereof. By discovering the novel biomarker for the diagnosis of uremic cardiomyopathy, uremic cardiomyopathy can be diagnosed early and an appropriate treatment method can be provided, which may contribute to improving patient prognosis, reducing medical costs, and the like.
Absstract of: US20260224660A1
The cardiac diastolic function-improving agent according to an embodiment of the present invention comprises a polynucleotide encoding a reprogramming factor polypeptide Gata4.
Absstract of: WO2026163010A2
A method of assessing expression profiles of miRNA markers using predictive classification models to distinguish between non-diseased and diseased mitral valve disease, non-diseased and diseased DCM, non-diseased and diseased HCM. Additionally, an assessment of the same method is provided to discriminate pre-clinical from clinical MMVD or DCM patients. Also provided is a method of differentially diagnosing MMVD patients from DCM patients or from healthy controls.
Absstract of: AU2025213424A1
The present invention relates to the field of disease treatment, and particularly to use of a reagent capable of inhibiting or knocking out Jun gene expression in the treatment of heart failure with preserved ejection fraction (HFpEF) and a method for drug screening.
Absstract of: WO2026156121A1
The present disclosure relates generally to the treatment of subjects having a lipid disorder or a cardiovascular disease or at risk of developing a lipid disorder or a cardiovascular disease by administering a Phospholipase A2 Group XIIB (PLA2G12B) inhibitor to the subject.
Absstract of: US20260207775A1
The invention relates to the field of diseases caused by high levels of LDL-C and/or fibrinogen, such as cardiovascular disease. The invention involves oligonucleotides for RNA editing technology in deaminating target adenosine nucleotides, such as the adenosine at position 1055, in transcripts of the human B4GALT1 gene.
Absstract of: US20260210975A1
0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.
Absstract of: US20260209290A1
Disclosed is a method, a pharmaceutical composition, and a pharmaceutical preparation for prevention and/or treatment of pulmonary arterial hypertension (PAH). The method includes administering to a subject at least one of a first agent that inhibits binding of Hic-5 to SMAD7 or a second agent that inhibits Hic-5.
Absstract of: CN122424338A
The invention relates to application of SIRT5 as an abdominal aortic aneurysm treatment target, and relates to the technical field of biological medicine. It is confirmed for the first time that expression of SIRT5 in human abdominal aortic aneurysm tissues, animal models and pathological stimulated vascular smooth muscle cells is significantly up-regulated and is closely related to phenotypic transformation of the vascular smooth muscle cells, occurrence and development of AAA can be significantly inhibited by specifically knocking out SIRT5 from the vascular smooth muscle cells, and the pathological process of AAA is aggravated by overexpression of SIRT5, so that the AAA can be effectively inhibited. The SIRT5 can be used as an intervention target of AAA, and in an animal model, it is proved that MC3482 can significantly inhibit formation of abdominal aortic aneurysm, a brand-new drug intervention target and a candidate compound are provided for abdominal aortic aneurysm, and a solid foundation is laid for treatment of abdominal aortic aneurysm and subsequent drug development.
Absstract of: CN122399027A
The invention provides application of an ATP6v0a1 regulating agent in preparation of a medicine for preventing and/or relieving and/or treating dilated cardiomyopathy and/or heart failure. The application provided by the invention provides a brand new molecular target for the treatment of DCM and heart failure; furthermore, the ATP6v0a1 regulating agent provided by the invention can be used for effectively treating dilated cardiomyopathy and heart failure, and has better treatment potential and specificity compared with a traditional symptomatic treatment medicine.
Absstract of: CN122405814A
The invention provides a biomarker RAB10 for diagnosing collateral circulation establishment and application of the biomarker RAB10, and belongs to the technical field of biomedicine. The new application of the RAB10 in the cardiovascular treatment field is found for the first time, the cognition that the existing research of the RAB10 is only limited to the tumor field is broken through, and the RAB10 is creatively applied to the brand new treatment scene of coronary artery collateral circulation establishment. A rigorous cell experiment proves that the proliferation, migration and angiogenesis of endothelial cells can be obviously promoted by the overexpression of the RAB10, which directly proves that the positive regulation and control effect of the RAB10 in angiogenesis and provides a direct experimental basis for the application of the RAB10 in therapeutic angiogenesis. The invention further provides that the RAB10 can be used as a biological marker for evaluating the collateral circulation establishment potential of the CTO patient, a new tool is provided for predicting the long-term prognosis of the patient and formulating an individualized treatment strategy, and the RAB10 has an important clinical transformation prospect.
Absstract of: WO2026152007A1
Disclosed are methods for assessing the likelihood of a subject developing coronary artery disease (CAD). The methods comprise determining a polygenic risk score based on a set of single nucleotide polymorphisms associated with endothelial cell function. The assessment may include the subject's LDL-C levels as a factor, and the methods include determining a subject's sensitivity to LDL-C mediated CAD. Determination of increased risk for CAD is followed by treatment with an anti-CAD therapy.
Absstract of: US20260201372A1
0000 Compositions and methods are disclosed for treating metabolic syndrome-associated heart disease cardiomyopathy and/or heart failure, wherein the method comprises the step of increasing the concentration of LIPTER RNA in the cardiomyocytes of said patient.
Absstract of: US20260201474A1
0000 The present disclosure relates generally to methods for accurately predicting the risk of cancer-associated venous thromboembolism (CAT) and/or preventing CAT in cancer patients using ctDNA as a biomarker.
Absstract of: WO2026148565A1
The use of annexin A2 (ANXA2) and an inhibitor thereof in the diagnosis, treatment and/or prevention of pulmonary hypertension. Specifically disclosed is the use of an ANXA2 inhibitor (comprising an siRNA for silencing the ANXA2 gene, an ANXA2 antibody, and a phosphorylation inhibitor) in the preparation of a product for preventing and/or treating pulmonary hypertension. It is verified in experiments that the ANXA2 inhibitor can significantly inhibit the proliferation and migration of pulmonary arterial smooth muscle cells, and significantly ameliorate pulmonary hypertension, pulmonary arterial vascular remodeling, and right ventricular hypertrophy. The ANXA2 or ANXA2 protein Thr208 phosphorylation site can be used in the diagnosis or assisted diagnosis of pulmonary hypertension, or in the screening of drugs for pulmonary hypertension and the development of new diagnostic and therapeutic methods and drugs. The developed therapeutic target and ANXA2 inhibitor have a high clinical application value in the fields of diagnosis, prevention, and treatment of pulmonary hypertension.
Nº publicación: WO2026149323A1 16/07/2026
Applicant:
SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD [CN]
SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD.
Absstract of: WO2026149323A1
Provided are the methods of use and pharmaceutical compositions of mitochondrial uncouplers and glucagon-like peptide-1 receptor agonists for treating various diseases and conditions, including obesity, T2DM, liver diseases and conditions (e.g., MASH), and cardiovascular diseases and conditions(e.g.,heart failure).
BOPI
Electronic site
